ARMANI: switch maintenance with ramucirumab & paclitaxel in G/GEJ cancer 

Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy, discusses the Phase III ARMANI trial (NCT02934464) which examined the benefits of switch maintenance or early second-line therapy in patients with HER2-negative advanced gastric/gastroesophageal (G/GEJ) cancer. Patients were randomized to ramucirumab plus paclitaxel or additional CAPOX/FOLFOX followed by fluoropyrimidine monotherapy. A significant improvement in progression-free survival (PFS) and overall survival (OS) was observed in patients receiving ramucirumab and paclitaxel. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.